RAG-17 is an experimental RNA-targeting therapy designed to lower toxic SOD1 protein in people with SOD1-ALS. A six-person trial found RAG-17 was well tolerated, with no serious side effects. RAG-17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results